Information Library
Results for: White Papers - Faster product development - High-quality studies
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer
June 23, 2011
In this new white paper Quintiles’ experts Christopher Ung, Jason Hill, Carrie Lee and Harish Dave review some of the most promising molecular pathways and targeted approaches for NSCLC, the critical role of diagnostics, and strategies to detect and address the emergence of resistance. -
Asia
March 8, 2011
This paper examines new development models as Western companies seek to develop and register their products in Asia, while emerging Asian companies seek new capabilities to globalize products. -
Is a REMS Request from FDA More Likely for Drugs & Biologics Indicated for Pediatric Use?
October 8, 2010
Is a REMS Request From FDA More Likely For Drugs and Biologics Indicated for Pediatric Use? -
Advancing Oncology Care Through Innovative Treatment Approaches
September 22, 2010
In this new white paper, Quintiles’ oncology experts Harish Dave and Eric Groves summarize the new findings and promising results presented at the June ASCO 2010 meeting. -
Managing Pharmacovigilance as a Business
July 28, 2010
The three steps required to develop a strategic approach to global capacity management. -
Regulations for Clinical Studies in Pediatric Patients in the European Union
March 10, 2010
After the United States issued pediatric drug study requirements, the European Union (EU) passed a regulation that created major changes to clinical studies for pediatric -
Reinventing the Clinical Trial
March 31, 2009
As a new era of drug discovery unfolds, reinventing the clinical trial is essential to medical advancement. -
Advancing Drug Development Through Pharmacogenomics
March 31, 2009
Pharmacogenomics (PG x) is the study of how such genetic differences influence drug therapy. The goal is to use a person’s DNA profile to predict how the individual will respond to a medicine. The ability to predict drug response holds enormous promise to advance the drug development process and to improve drug safety and effectiveness in medical practice. -
Monitoring for Quality
May 22, 2008
Scott Cooley, Executive Director, Phase IIIb/IV Product Management, Quintiles, discusses innovative and traditional resources in a risk-based monitoring program.
Page 1 of 1 (9 results)
